KoreaTimes - Bio

The Korea Times

Entertainment & Arts

SCMP
Asia

The Korea Times

Entertainment & Arts

SCMP
Asia

The Korea Times

Business

Bio

Sat, March 25, 2023 | 19:00

Medytox takes patent fight with Hugel to USITC

Medytox takes patent fight with Hugel to USITC

Another patent war among domestic botulinum toxin (BTX or Botox) makers has broken out after Medytox accused its local competitor, Hugel, of stealing its BTX strains, filing a lawsuit with the United States International Trade Commission (USITC), according to company officials, Tuesday.

Baek Byung-yeul | 2022-04-05 16:47

Samsung Biologics eyes global market with acquisition of Samsung Bioepis: CEO

Samsung Biologics eyes global market with acquisition of Samsung Bioepis: CEO

Samsung Biologics, the biotech arm of Korea's Samsung Group, aims to expand its presence in the global market through full ownership of Samsung Bioepis, its chief executive said Tuesday.

2022-03-29 15:35

Regulator fines 3 Celltrion firms 13 bln won for violating accounting rules

Regulator fines 3 Celltrion firms 13 bln won for violating accounting rules

South Korea's financial regulator said Wednesday that it has fined three companies of pharmaceutical giant Celltrion a combined 13 billion won (US$10.5 million) for violating accounting rules.

2022-03-16 19:26

GL Rapha declines to halt Russian vaccine production in Korea

GL Rapha declines to halt Russian vaccine production in Korea

GL Rapha, one of the Korean manufacturers of Russia's Sputnik V and one-shot Sputnik Light coronavirus vaccines, has reaffirmed that it will continue producing and exporting the vaccines. The move contrasts with Huons Global, which decided recently to halt production of the Russian vaccines in Korea.

Park Jae-hyuk | 2022-03-11 14:12

Korea on right track, but long way to go to becoming vaccine hub

Korea on right track, but long way to go to becoming vaccine hub

Samsung Biologics, SK Bioscience and other biotech companies here are expanding their vaccine development and manufacturing capabilities, as the COVID-19 pandemic has highlighted the importance of having vaccine sovereignty, according to company officials Tuesday. Korea had a hard time securing COVID-19 vaccines when they were first available because the nation was at the mer...

Baek Byung-yeul | 2022-03-08 13:27

Ex-Beckman Coulter executive to lead Seegene's US office

Ex-Beckman Coulter executive to lead Seegene's US office

Richard S. Creager, a former chief science officer of U.S.-based medical diagnostics company Beckman Coulter, was appointed as CEO of Korean diagnostics company Seegene's U.S. subsidiary.

Baek Byung-yeul | 2022-03-03 14:25

Sputnik vaccine manufacturers in Korea wary of Russia sanctions

Sputnik vaccine manufacturers in Korea wary of Russia sanctions

Korea's contract development and manufacturing organizations (CDMOs) are facing concerns about a potential setback in their production of the Sputnik V and one-shot Sputnik Light vaccines against COVID-19, after the U.S. and the European Union began imposing tougher financial sanctions against Russia over its invasion of Ukraine.

Park Jae-hyuk | 2022-02-25 14:24

Escalating Ukraine crisis to weigh further on Korean exporters

Celltrion 2021 net soars 20% on robust overseas sales

Celltrion 2021 net soars 20% on robust overseas sales

Celltrion said Wednesday that its net profit jumped 20.1 percent year-on-year last year on the back of robust sales of its biosimilar products in overseas markets.

2022-02-16 14:59

HLB's US affiliate Verismo sets up Asia headquarters in Korea

HLB's US affiliate Verismo sets up Asia headquarters in Korea

Verismo Therapeutics, a new drug development company based in the U.S., established its Asia branch in Korea as part of its plan to facilitate clinical trials of its anti-cancer drug platform in the Asia region, the Korean biotech company HLB said Tuesday.

Baek Byung-yeul | 2022-02-15 17:16

Samsung Biologics to begin operations of 4th plant this year

Samsung Biologics to begin operations of 4th plant this year

Partial operations will begin in October of this year at Samsung Biologics' fourth plant currently being built in Songdo, west of Seoul. The move is part of efforts by the drug-manufacturing unit of Samsung Group to improve its capabilities in the contract manufacturing organization (CMO) business, its CEO said Thursday.

Baek Byung-yeul | 2022-01-13 16:24

1 2 3 4 5 6 7 8

Top 10 Stories

1	Zoo shares sad story of what caused Sero the zebra to escape

2	Burnout: Cardiothoracic surgery residents work 102 hours a week

3	Churches, Seoul gov't unite to fight low birthrate

4	North Korea will pay price for reckless provocations, warns Yoon

5	Genesis launches 2023 G90 sedan

6	Second daughter of Daesang chairman promoted to vice president

7	What's next for Do Kwon?

8	More companies adopt electronic voting amid increase in shareholder activism

9	Samsung Display strike looms due to deadlocked wage negotiations

10	Over 70% of firms unwilling to embrace longer workweek

DARKROOM